ACUMEN PHARMACEUTICALS INC. - COMMON STOCK

1,2300

16-сентября-25 13:00:33

15 мин. задержка

Акции

-0,0300

-2,38%

Сегодняшний диапазон

1,2100 - 1,2950

ISIN

N/A

Источник

NASDAQ

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

26 авг 2025 13:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

12 авг 2025 04:00:01 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

05 авг 2025 13:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025

28 июл 2025 05:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

15 июл 2025 04:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

10 июл 2025 05:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

13 май 2025 04:00:01 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

07 май 2025 13:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

06 май 2025 13:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

02 апр 2025 04:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

27 мар 2025 04:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

26 мар 2025 05:00:01 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

20 мар 2025 13:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

19 мар 2025 05:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

12 мар 2025 05:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

10 мар 2025 13:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

09 янв 2025 05:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

26 ноя 2024 13:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

12 ноя 2024 04:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

11 ноя 2024 13:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.